Associated Genetic Biomarkers
Phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma (PIK3C2G) is a gene that encodes a protein that is a member of the phosphoinositide 3-kinase family. The protein is involved in cell signaling pathways that regulate cell proliferation, onogenic transformation, cell survival, cell migration, and intracellular protein trafficking. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as cancers of the biliary tract, intestinal cancer, and skin cancer.
PIK3C2G is altered in 3.00% of all cancers with lung adenocarcinoma, cutaneous melanoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in PIK3C2G are PIK3C2G Mutation (2.05%), PIK3C2G Amplification (0.57%), PIK3C2G Loss (0.11%), PIK3C2G R738C (0.04%), and PIK3C2G E1394K (0.03%) .
PIK3C2G status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PIK3C2G status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with PIK3C2G status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is PIK3C2G Mutation .
Paxalisib and radiation therapy are the most frequent therapies in trials with PIK3C2G as an inclusion criteria .
Significance of PIK3C2G in Diseases
Malignant Solid Tumor +
PIK3C2G is altered in 3.27% of malignant solid tumor patients .
PIK3C2G is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3C2G status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.